Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Sarcoma 3Glioblastoma 3Small Cell Lung Carcinoma 1Recurrence 1Prostatic Neoplasms 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Ichthyosis, X-Linked 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Temozolomide 42Magnetic Resonance Spectroscopy 41Radiotherapy 22Specimen Handling 18Biopsy 13X-Rays 10Radiation 10trametinib 8Bevacizumab 8Nivolumab 7Blood Specimen Collection 7olaparib 6fluorodopa F 18 6dabrafenib 6Radiotherapy, Intensity-Modulated 6Phantoms, Imaging 6Nuclear Medicine Department, Hospital 6Lomustine 6pembrolizumab 5abemaciclib 5Standard of Care 5vorasidenib 4ulixertinib 4larotrectinib 4ivosidenib 4erdafitinib 4Surgical Procedures, Operative 4Dianhydrogalactitol 4Cyclophosphamide 4Aminolevulinic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioma × ADI PEG20 × 1 year × Clear all
NCT07389278 2026-02-05

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

University of California, San Francisco

Phase 1/2 Not yet recruiting
97 enrolled
CNS

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡